Mergers, acquisitions, and restructuring - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mergers, acquisitions, and restructuring
A roundup of company moves and positioning from the pharmaceutical and biotechnology industries and contract service providers.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 9

London (Aug. 9)— Hikma Pharmaceuticals, a multinational pharmaceuticals group, agreed to acquire the entire issued share capital of Alkan Pharma, an Egyptian pharmaceuticals company, for a cash consideration of $60.5 million. The acquisition is scheduled to be completed in the second half of 2007, subject to meeting certain regulatory requirements. The acquisition will be funded entirely by debt.

New York (Aug. 8)American Oriental Bioengineering, a manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, signed a legally binding letter of intent to acquire Guangxi Boke Pharmaceutical, a privately owned plant-based healthcare company, in a transaction valued at approximately $40.0 million.

Bad Vilbel, Germany (Aug. 3)Stada acquired the Russian pharmaceuticals group Makiz through a contract on the purchase of 100% of the shares of Zao Makiz-Pharma, Zao Skopinpharm and Zao Biodyne Pharmaceuticals. The contract was concluded by Stada's Russian subsidiary Nizhpharm Oao, Nizhny Novgorod. The staggered purchase price, which partly depends on the results of fiscal year 2007, is expected to amount to a total of approximately EUR 125 million ($172 million) less net debt of the group at closing, but will be EUR 135 million ($186 million) at maximum.

Los Angles, CA (Aug. 1)Abraxis BioScience, a biopharmaceutical company, acquired from Watson Pharmaceuticals a sterile injectable manufacturing facility located in Phoenix, Arizona. This facility, which has the ability to manufacture lyophilized powders, suspension products, and aqueous and oil solutions, currently manufactures products for Watson and other third parties.

South San Francisco, CA (Aug. 2)Genentech announced that the waiting period under the Hart-Scott-Rodino Act has expired and it has completed the acquisition of Tanox, Inc. Tanox shareholders approved the merger agreement on January 15, 2007.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here